* Additional information regarding NVSS is available at http://www.cdc.gov/nchs/ nvss.htm. † Additional information regarding the SEER program is available at http://seer. cancer.gov. § Based on International Classification of Diseases, Tenth Revision codes for leukemias (C91.0-C91.4, C91.7, C91.9, C92.0-C92.5, C92.7, C92.9, C93.0-C93.2, C93.7, C93.9, C94.0, C94.2, C94.4, C94.5, and C95.0) and brain and other nervous system neoplasms (C70-C72). ¶ Additional information regarding SEER-Stat is available at http://seer.cancer.gov/ seerstat.
Trends in Childhood Cancer Mortality -United States, 1990-2004
Cancer is the fourth most common cause of death (after unintentional injury, homicide, and suicide) among persons aged 1-19 years in the United States (1, 2) . Because recent childhood cancer mortality has not been well characterized in terms of temporal, demographic, and geographic trends (2, 3) , CDC analyzed cancer death rates among children (defined as aged 0-14 years) and adolescents (defined as aged 15-19 years) for the period 1990-2004 by sex, age group, race, ethnicity, U.S. Census region, and primary cancer site/leading diagnosis, using the most recent data available from the National Vital Statistics System (NVSS). This report describes the results of that analysis, which indicated that, overall, age-adjusted childhood cancer death rates decreased significantly during 1990-2004 among both sexes, both age groups, all races (except American Indians/Alaska Natives [AI/ANs]), Hispanics, non-Hispanics, and all U.S. Census regions. However, decreases in death rates varied among U.S. Census regions and between Hispanics and non-Hispanics. Eliminating racial/ethnic health disparities is one of the overarching goals of Healthy People 2010 (4) . Further research is needed to understand geographic and ethnic disparities in childhood cancer death rates. Moreover, cancer prevention and intervention measures should be designed to reach populations that are underserved and at high risk.
NVSS collects death certificate data from vital statistics offices in the 50 states and the District of Columbia. * All reported deaths among children and adolescents during 1990-2004 were included in this analysis. Population estimates used as denominators in death rate calculations were from the U.S. Bureau of the Census and were modified by the Surveillance, Epidemiology, and End Results (SEER) program (1) . † Age-adjusted death rates and trends were calculated for all primary cancer sites combined and for the two leading cancer diagnoses: leukemias and brain and other nervous system neoplasms. § All rates were per 1 million population and age adjusted to the 2000 U.S. standard population. For all primary cancer sites/leading diagnoses combined, death rates and trends were stratified further by sex, age, race, ethnicity, and U.S. Census region. Rates and overall annual percentage changes (APCs) from 1990 to 2004 were calculated using SEER-Stat. ¶ Joinpoint regression was performed to determine statistically significant changes in trends during 1990-2004 (5). The overall statistical significance level was α = 0.05, with a maximum of three joinpoints and four line segments allowed (5) .
A total of 34,500 childhood cancer deaths were reported in the United States during 1990-2004. A total of 2,223 cancer deaths occurred in 2004; among these, leukemias were the most common diagnoses (25.5%), followed by brain and other nervous system neoplasms (25.0%) ( Figure 1 ). From 1990 to 2004, death rates declined significantly for leukemias by 3.0% per year, for brain and other nervous system neoplasms by 1.0% per year, and for all other cancers combined by 1.3% per year (Table) .
For all cancers combined during 1990-2004, boys (33.1 per million) had significantly higher death rates than girls (26.1); adolescents (37.9) had significantly higher death rates than children (26.9); whites (30.1) and blacks (29.3) had significantly higher death rates than Asians/Pacific Islanders (A/PIs) (26.4) and AI/ANs (20.0), respectively; and Hispanics (30.3) had significantly higher death rates than non-Hispanics (29.1) ( Table) . Death rates decreased similarly by sex, age group, and race; decreases ranged from 1.5% to 2.0% per year during 1990-2004. However, APCs, reflecting a decline in death rates, differed by 60% between Hispanics and non-Hispanics: 1.0% per year for Hispanics compared with 1.6% per year for non-Hispanics. Statistical analysis with joinpoint regression revealed that the death rate for whites remained stable during 1990-1992 (p = 0.77), declined significantly during 1992-1996 by 4.3% per year (p = 0.001), and then stabilized again during 1996-2004 (p = 0.07) (Figure 2 ). Death rates for blacks and A/PIs declined significantly, both by 1.6% per year (p<0.001 for blacks and p = 0.003 for A/PIs). Death rates for AI/ANs were stable during 1990-2004 (p = 0.18); this trend might be attributed to the small numbers available for 
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Acute lymphocytic leukemia accounts for approximately 73% of childhood leukemia cases (1) . Likely because of advances in treatment, such as chemotherapy and bone marrow transplantation, substantial improvement has occurred in survival rates for children and adolescents with acute lymphocytic leukemia (7) . In this analysis, death rates declined substantially for childhood leukemias during 1990-2004, which is consistent with findings from previous trend analyses for the period 1975-1995 (3) . For brain and other nervous system neoplasms, death rates declined significantly during 1990-2004. Five-year relative survival rates for brain and other nervous system neoplasms also have improved (1, 7) .
The results of this analysis indicate geographic disparities in childhood cancer death rates. During 1990-2004, childhood cancer death rates in the West were the highest among all U.S. Census regions and were the slowest to decline. The causes of these disparities cannot be determined based on the data available and need to be explored by further studies, including cancer survival studies. Moreover, variations by ethnicity were observed. Hispanics and non-Hispanics had similar childhood cancer death rates in 1990, but these rates declined more rapidly for non-Hispanics than for Hispanics during 1990-2004. Studies have documented that Hispanics lack sufficient access to health-care services because of inadequate heathinsurance coverage, lack of health insurance, poor geographic access to health-care providers, lack of transportation to and from providers, and cultural and linguistic barriers (8) , which might contribute to this disparity. However, differences in tumor aggressiveness, cancer stage at diagnosis, and response to treatment also should be considered.
The findings in this report are subject to at least five limitations. First, the reporting of race/ethnicity to the U.S. Bureau of the Census and on death certificates usually is reliable for blacks and whites; however, death rates for American Indians, A/PIs, and Hispanics are underestimated by 21%, 11%, and 2%, respectively (9) . Second, the ability to stratify death rates for each primary cancer site/leading diagnosis by demographic and geographic variables and to assess the geographic variation at the state or county level was limited because of low death counts. Third, causes of death might be misclassified on death certificates. Fourth, using the 2000 U.S. standard population for all study years might not reflect actual annual population. Finally, cancer deaths among boys and girls who had cancer diagnosed as children but who died as adolescents are reflected in adolescent mortality rates. Thus, the mortality rates of adolescents might reflect the improved survival of children with cancer.
The overall trend of declining childhood cancer mortality during 1990-2004 likely reflects better treatment of childhood cancer. Surveillance of childhood cancer mortality should be well maintained to monitor the persistence of these declines. Possible causes for disparities in childhood cancer death rates (e.g., lack of health insurance, difficulty in accessing health care, late diagnosis, poor treatment quality, and unhealthy behaviors and lifestyles) need to be studied 35   40   1989  1990  1991  1992  1993  1994  1995  1996  1997  1998  1999  2000  2001  2002  2003 2004
Surveillance for Travel-Associated Legionnaires DiseaseUnited States, 2005-2006
An estimated 8,000-18,000 persons are hospitalized with Legionnaires disease (LD) each year in the United States (1) , and approximately 20% of reported LD cases are associated with travel (2). Outbreaks of travelassociated LD can be difficult to detect because travelers disperse and Legionella-specific diagnostic tests are underutilized (3) . Consequently, clinicians and health departments often are unaware when more than one LD case is associated with a common travel destination. In 2005, the Council of State and Territorial Epidemiologists (CSTE) adopted a position statement recommending enhanced surveillance measures for LD, with emphasis on diagnosis and reporting of confirmed travel-associated LD cases within 7 days.* The rationale for enhanced surveillance was that earlier detection might lead to more rapid identification of a source (e.g., cooling tower) and expedite prevention measures (e.g., cleaning and chlorination). To 1) assess data from 32 states that used a supplementary reporting system for LD, 2) describe the epidemiology of travel-associated LD, and 3) compare characteristics of travel-associated cases with those of cases not associated with travel, CDC analyzed LD cases reported via the supplementary system during 2005-2006. The results of that analysis indicated that the proportion of LD cases that were travel associated remained stable from 2005 (23%) to 2006 (25%), the proportion of travel-associated cases reported via a dedicated CDC e-mail address increased from 11% to 24%, and the number of reported clusters of travelassociated LD increased from two in 2005 to eight in 2006. These results suggest that, to fully assess the benefits of enhanced LD surveillance, more states will need to adopt the CSTE recommendations.
LD cases are reported to CDC through the National Notifiable Diseases Surveillance System (NNDSS); this system collects certain patient demographic information (e.g., age and state of residence) but not travel history. Since 1980, states have had the option of additionally reporting more detailed information voluntarily to CDC through a supplementary LD reporting system, using a paper case-LD report form † that defines confirmed cases of LD and collects information related to diagnostic testing, location of disease acquisition (i.e., community or hospital), and travel. For this analysis, only confirmed LD cases were included. In 2005 and 2006, totals of 2,301 and 2,834 cases of LD, respectively, were reported to NNDSS, of which 603 (26%) and 729 (26%) cases, respectively, also were reported via the supplementary system (4, 5 The proportion of LD cases diagnosed by culture has declined since introduction of urine antigen testing (2) , and tests are performed on only a limited proportion of patients who have indications for urine antigen testing or Legionella culture of respiratory specimens (6) . Despite the convenience of urine antigen testing, the availability of a clinical isolate of Legionella improves the likelihood that an environmental source for Legionella can be identified (i.e., by matching the characteristics of clinical and environmental isolates) and remediated (7, 8) . In addition, CDC recently implemented DNA sequence-based typing to compare individual clinical strains of Legionella among travelers. Strain typing has contributed to identification of clusters of travel-associated LD in Europe (9) and might provide similar benefits in the United States. Therefore, CDC is requesting that state health departments forward to CDC all clinical isolates of Legionella obtained from persons who report that they traveled during the 2-14 days before onset of illness. Details regarding the isolate submission process can be obtained by e-mail (travellegionella@cdc.gov) or by telephone (404-639-0418).
The findings in this report are subject to at least five limitations. First, because analysis was limited to 2005-2006 and the CSTE position statement was adopted in 2005, sufficient time might not have elapsed to attribute changes in LD reporting to the CSTE statement. Second, the data presented likely underestimate the number of cases of LD because diagnostic tests for LD are underutilized in the United States. Utilization might increase as more clinicians follow recently updated guidelines for management of community-acquired pneumonia, including LD (10). Third, travel-associated LD cases might be underestimated because not all clinicians obtain a travel history from all patients with community-acquired pneumonia. Fourth, although an increase in reporting by e-mail might suggest more rapid reporting, timeliness of reporting could not be assessed because the dates that reports were received by CDC were not recorded. Finally, although all states are required to report LD to NNDSS, only 26% of these LD cases also were reported via the voluntary supplementary system during [2005] [2006] . Therefore, the detailed data provided on case-report forms might not be representative of all reported LD cases.
Identification of a single case of LD suggests the possibility of an environmental source to which other persons might be exposed. Therefore, timely reporting all cases of travel-associated LD to CDC is important for identifying clusters. CDC encourages state health departments to post information on LD cases associated with travel on the CDC Epidemic Information Exchange (Epi-X) to alert other health officials to review their records for cases of LD associated with travel to the same destination. During 2005-2006, a total of 30 Epi-X postings asked that cases of LD associated with travel to specific locations be reported to CDC or to the investigating state health department. CDC resources for investigating and reporting cases of travelassociated LD are available at http://www.cdc.gov/ legionella. CDC also continues to be available for consultation with regard to LD clusters.
Brief Report

Respiratory Syncytial Virus ActivityUnited States, July 2006-November 2007
Respiratory syncytial virus (RSV), the most common cause of severe lower respiratory tract disease among infants and young children, typically infects persons by age 2 years and can cause subsequent infections throughout life (1) . RSV infection primarily manifests as bronchiolitis or pneumonia and results in approximately 75,000 to 125,000 hospitalizations in the United States each year (1) . Persons at increased risk for severe disease or death include premature infants, older adults, and persons of any age with compromised respiratory, cardiac, or immune systems (2, 3) . RSV is transmitted from person to person via close contact, droplets, or fomites. In temperate climates, peak RSV activity typically occurs during the winter. However, yearto-year national and regional variability in the RSV season onset and offset* occurs in the United States (4). RSV circulation also varies by geographic location; for example, Florida has an earlier season onset and a longer season than the rest of the United States (5) . Using data reported to the National Respiratory and Enteric Virus Surveillance System (NREVSS), this report summarizes RSV temporal and geographic trends in the United States during the weeks ending No vaccine or effective therapy is available for RSV. Infants and children at risk for severe RSV infection can § SDI conducts RSV surveillance with support from MedImmune, Inc.
(Gaithersburg, Maryland). In fall 2006, CDC and SDI signed a memorandum of understanding to share RSV surveillance data to make the most complete RSV dataset available. The memorandum outlines the voluntary participation of laboratories, type of data shared, frequency of reporting, and approval and acknowledgements for data publication. The relationship between CDC and SDI is limited to data sharing, as outlined in the memorandum. CDC does not make recommendations regarding the administration of RSV immune prophylaxis. For additional information, contact NREVSS by e-mail at nrevss@cdc.gov.
* As defined by NREVSS, RSV national and regional season onset is the first of 2 consecutive weeks during which the median percentage of specimens testing positive for RSV antigen is >10%. RSV season offset is the last of 2 consecutive weeks during which the median percentage of positive specimens is >10%. receive immune prophylaxis with monthly doses of a humanized murine anti-RSV monoclonal antibody during the RSV season (8) . Specific immune prophylaxis guidelines are available from the American Academy of Pediatrics (8, 9 Month and year 
In anticipation of possible licensure of MCV4 for children aged 2-10 years, during February 2007-October 2007, the ACIP meningococcal vaccine workgroup reviewed data on MCV4 immunogenicity and safety in children in that age group. On the basis of these data, opinions of workgroup members, and feedback from partner organizations, the workgroup proposed recommendations for use of MCV4 among children aged 2-10 years who are at increased risk for meningococcal disease. The recommendations were approved by ACIP at its October 24, 2007, meeting.
In a single, randomized, modified double-blind, controlled study of healthy U.S. children aged 2-10 years that compared MCV4 with MPSV4, serum bactericidal antibody geometric mean titers against all four serogroups were significantly higher at both 28 days and 6 months after vaccination in the children who received MCV4 (3). In the same study, rates of most solicited local and systemic adverse events after vaccination with MCV4 were comparable to rates observed after vaccination with MPSV4 (3). Although duration of protective immunity from MCV4 is not yet known, conjugate vaccines generally have a longer duration of protection than polysaccharide vaccines (2) .
At its October meeting, ACIP revised its recommendation to state that MCV4 is preferable to MPSV4 for vaccination of children aged 2-10 years who are at increased risk for meningococcal disease. These children include travelers to or residents of countries in which meningococcal disease is hyperendemic or epidemic, children who have terminal complement component deficiencies, and children who have anatomic or functional asplenia (2). Additionally, MCV4 is preferred to MPSV4 for use among children aged 2-10 years for control of meningococcal disease outbreaks. Providers may elect to vaccinate children aged 2-10 years who are infected with human immunodeficiency virus (HIV).* For children aged 2-10 years who have previously received MPSV4 and remain at increased risk for meningococcal disease, ACIP recommends vaccination with MCV4 at 3 years after receipt of MPSV4. Children who last received MPSV4 more than 3 years ago and remain at risk for meningococcal disease should be vaccinated with MCV4 as soon as possible. For children at lifelong increased risk for meningococcal disease, subsequent doses of MCV4 likely will be needed. ACIP will make recommendations for revaccination with MCV4 as more data on duration of protection become available.
Persons with a history of Guillain-Barré syndrome (GBS) might be at increased risk for GBS after MCV4 vaccination (4); therefore, a history of GBS is a precaution (5) to administering MCV4. For children with a history of GBS, MPSV4 is an acceptable alternative for short-term (i.e., 3-5 years) protection against meningococcal disease.
The ACIP meningococcal vaccine workgroup is considering options for general use of MCV4 among children aged 2-10 years. Recommendations will be presented at a future ACIP meeting. Recommendations for use of MCV4 in persons aged 11-55 years, including a recommendation for routine vaccination with MCV4 of persons aged 11-18 years, have been published previously and remain unchanged (3, 6 On page 8, in Table 2 , in the first row, "Infants (<1 yr)," under the column heading "Combination vaccine, Pediarix, Dose (µg)," the text should read, "10."
On page 9, in Table 4 , under the column heading "Recommendation," the second bullet should read, "Administer 3 additional hepatitis B vaccine doses with single-antigen vaccine at ages 1, 2-3, and 6 mos or hepatitis B-containing combination vaccine at ages 2, 4, and 6 mos (Pediarix) or 2, 4, and 12-15 mos (Comvax). † "
The fourth bullet should read, "Test for HBsAg and antibody to HBsAg 1-2 mos after completion of >3 doses of a licensed hepatitis B vaccine series (i.e., at age 9-18 mos, generally at the next well-child visit). Testing should not be performed before age 9 mos nor within 4 wks of the most recent vaccine dose."
The seventh bullet should read, "Administer 3 additional hepatitis B vaccine doses with single-antigen vaccine at ages 1, 2-3, and 6 mos or hepatitis B-containing combination vaccine at ages 2, 4, and 6 mos (Pediarix) or 2, 4, and 12-15 mos (Comvax). † "
The 10th bullet should read, "Complete the hepatitis B vaccine series with single-antigen vaccine at ages 2 mos and 6-18 mos or hepatitis B-containing combination vaccine at ages 2, 4, and 6 mos (Pediarix) or 2, 4, and 12-15 mos (Comvax). † "
The following footnote should be added to Table 4 : " † The final dose in the vaccine series should not be administered before age 24 weeks (164 days)."
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